The originator of the data must be clearly identified.

Legible: Data must be readable and permanent.

Contemporaneous: Data must be recorded at the time of activity.

Original: The data source must be maintained.

Accurate: The data must reflect the actual observations.

ALCOA+ extends these principles further to include:

• Complete – All data including changes and deletions
• Consistent – Date/time format, sequence, and control
• Enduring – Data must be durable and long-lasting
• Available – Accessible for review during audits and inspections

ALCOA+ is now a global standard accepted by EMA, CDSCO, MHRA, WHO, and other agencies.

3. Regulatory Guidelines and Global Expectations

Data integrity is addressed explicitly by various agencies:

• USFDA: Guidance on Data Integrity and Compliance with cGMP
• MHRA: GxP Data Integrity Definitions and Guidance (2018)
• WHO: Annex 5, TRS 996 for GMP and laboratory compliance
• EMA: EudraLex Volume 4, Annex 11 (electronic records) and Chapter 4 (documentation)

These bodies expect validated systems, audit trails, and procedures to be in place for ensuring traceability, data security, and real-time documentation. For a complete understanding of data lifecycle mapping, visit Pharma Regulatory.

4. Where Data Integrity Matters

Data integrity must be applied across the following operations:

Manufacturing:

• Batch Manufacturing Records (BMR)
• Equipment usage logs and cleaning records
• Process parameters and control data

Quality Control:

• Chromatography data systems (CDS)
• Balance, pH meter, UV spectrophotometer logs
• Raw data and result calculations

Stability Testing:

• Pull schedules and environmental conditions
• Documentation of stability failures

To explore stability-specific documentation and ALCOA+ formats, visit Stability Studies.

5. Common Data Integrity Issues and Real-World Findings

Regulatory audits have revealed:

• Use of unofficial notebooks or scrap paper for recording data
• Backdating or pre-dating entries
• Failure to maintain original raw data
• Inadequate audit trails for electronic data
• Uncontrolled user access in computerized systems

For example, an FDA 483 observation noted “Analyst deleted HPLC runs without scientific justification,” which raised concerns over falsification. Learn how to avoid such lapses with SOPs from Pharma SOP.

6. Implementing Data Integrity Policies and Governance

Steps to ensure compliance include:

1. Create a data integrity policy aligned with ALCOA+
2. Train all personnel on GDP, ALCOA+, and risk awareness
3. Conduct data mapping to understand the entire data lifecycle
4. Establish audit trail review procedures
5. Implement periodic data integrity self-assessments

GxP computer systems must be validated per CSV protocols to support data reliability. Visit Pharma Validation for validation templates and system requirements.

7. Controls in Electronic Systems

Regulators demand strict oversight of computerized systems:

• Enable audit trails that cannot be disabled
• Restrict user roles with tiered access
• Ensure data is backed up and protected from deletion
• Track all data modifications and record reasons
• Conduct periodic audit trail reviews

21 CFR Part 11 and EU Annex 11 provide guidance on electronic signatures, access control, and record retention in electronic formats.

8. Training and Culture of Data Integrity

Building a data integrity culture is vital. Employees must:

• Understand the importance of recording data contemporaneously
• Recognize what constitutes falsification or misconduct
• Feel empowered to report issues or gaps

Organizations should integrate data integrity awareness into annual training plans and monitor employee competency with assessments. Templates and checklists can be found on Pharma SOP.

9. Auditing for Data Integrity

Internal audits must evaluate:

• Completeness of records, logbooks, and data sets
• Proper use of error correction and version control
• Functionality of audit trails
• System access logs and admin override controls

CAPA should be implemented promptly where data gaps are observed. External audits, especially from regulators, heavily focus on lab data and computerized system compliance. Refer to Pharma GMP for audit readiness guides.

10. Conclusion

Data integrity is not just a technical requirement — it is a cultural foundation of quality and trust in pharmaceuticals. By implementing ALCOA+ principles, validating computerized systems, auditing processes regularly, and training personnel, companies can protect themselves from regulatory risks and uphold product quality and patient safety.

Establishing a sustainable data integrity program requires cross-functional collaboration and a risk-based approach. Stay compliant, build trust, and ensure success through vigilant, transparent, and ethical data practices.

Access SOP templates, training modules, and regulatory checklists on Pharma SOP, Pharma Validation, and Pharma Regulatory.